Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 17/20 | 0.57 |
| ▸ | KDR | P35968 | 12/20 | 0.53 |
| ▸ | SRC | P12931 | 4/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | HCK | P08631 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.53 |
| ▸ | PRKDC | P78527 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.53 |
| ▸ | CASK | O14936 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405191 | 1.00 | RET (0.57) | RETKDRSRCPIK3CDABL1 | |
| Trifluoroacetic Acid SCHEMBL29669791 | 0.92 | RET (0.54) | RETKDRSRCPIK3CDABL1 | |
| Trifluoroacetic Acid SCHEMBL21528139 | 0.92 | RET (0.54) | RETKDRSRCPIK3CDABL1 | |
| SCHEMBL21528193 | 0.92 | RET (0.63) | RETKDRSRCPIK3CDABL1 | |
| SCHEMBL30404443 | 0.92 | RET (0.63) | RETKDRSRCPIK3CDABL1 | |
| SCHEMBL20553584 | 0.86 | RET (0.58) | RETKDRSRCPIK3CDABL1 | |
| SCHEMBL28353780 | 0.86 | RET (0.56) | RETKDRSRCPIK3CDABL1 | |
| SCHEMBL26061261 | 0.86 | RET (0.54) | RETKDRSRCABL1 | |
| Trifluoroacetic Acid SCHEMBL21528199 | 0.85 | RET (0.55) | RETKDRSRCPIK3CDABL1 | |
| Trifluoroacetic Acid SCHEMBL29669754 | 0.85 | RET (0.55) | RETKDRSRCPIK3CDABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| EP-3788049-A1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788050-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112368289-A | C26-linked rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3619216-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110770243-A | Rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Revolution Medicines, Inc. | 2019-11-07 | — | — | US | disclosed |
| WO-2018204416-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | RET 1512/4885KDR 3263/4885SRC 971/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | RET 1512/4885KDR 3263/4885SRC 971/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | RET 1512/4885KDR 3263/4885SRC 971/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | RET 1666/4885KDR 2576/4885SRC 715/4885 |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | RET 1512/4885KDR 3263/4885SRC 971/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | RET 1666/4885KDR 2576/4885SRC 715/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | RET 573/4885KDR 2661/4885SRC 148/4885 |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | RET 1560/4885KDR 2961/4885SRC 579/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | RET 943/4885KDR 3134/4885SRC 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.